VIA Pharmaceuticals Inc (VIAP) Gagner

VIA Pharmaceuticals, Inc. is a biotechnology company, which engages in the development of compounds for the treatment of cardiovascular diseases. The company is headquartered in San Francisco, California and currently employs 6 full-time employees. The company went IPO on 2000-04-18. The Company’s lead compound, VIA-2291, targets an unmet medical need of reducing atherosclerotic plaque inflammation, which is an underlying cause of atherosclerosis and its complications. Atherosclerosis is a cardiovascular disease that results from chronic inflammation and the build-up of plaque in arterial blood vessel walls. The Company’s clinical development strategy integrates several technologies to provide clinical proof-of-concept, as early as possible in the clinical development process. These technologies include the measurement of biomarkers, medical imaging of the coronary and carotid vessel walls to evaluate the plaque characteristics, and atherosclerotic plaque bioassays.